However, individual results vary based on genetics, metabolism, and adherence
The recently published randomised controlled Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT) demonstrated that tirzepatide (up to 15 mg) was non-inferior to dulaglutide (1.5 mg) in reducing major adverse cardiovascular events (death from cardiovascular causes, myocardial infarction or stroke) in patients with T2DM and atherosclerotic CVD
and one published human clinical study examining intra-articular injection in 12 patients with chronic knee pain, of whom 7 out of 12 reported relief lasting over 6 months [15]
Hamlet Gasoyan, DS, Ph.D., MPH, a researcher with Cleveland Clinic's Center for Value-Based Care Research, led the study
Other research found that placebo, or fake injections, worked just as well as hCG injections for treating obesity